Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 June 2017Website:
http://www.avenuetx.comNext earnings report:
18 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 20 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
ATXI Latest News
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences:
- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 –
Avenue Therapeutics (NASDAQ: ATXI ) stock is rising higher after the company revealed a major investment from Robert Davidow. According to a filing with the Securities and Exchange Commission (SEC), Davidow now holds a 14.5% stake in the specialty pharmaceutical company.
What type of business is Avenue Therapeutics?
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
What sector is Avenue Therapeutics in?
Avenue Therapeutics is in the Healthcare sector
What industry is Avenue Therapeutics in?
Avenue Therapeutics is in the Biotechnology industry
What country is Avenue Therapeutics from?
Avenue Therapeutics is headquartered in United States
When did Avenue Therapeutics go public?
Avenue Therapeutics initial public offering (IPO) was on 27 June 2017
What is Avenue Therapeutics website?
https://www.avenuetx.com
Is Avenue Therapeutics in the S&P 500?
No, Avenue Therapeutics is not included in the S&P 500 index
Is Avenue Therapeutics in the NASDAQ 100?
No, Avenue Therapeutics is not included in the NASDAQ 100 index
Is Avenue Therapeutics in the Dow Jones?
No, Avenue Therapeutics is not included in the Dow Jones index
When was Avenue Therapeutics the previous earnings report?
No data
When does Avenue Therapeutics earnings report?
The next expected earnings date for Avenue Therapeutics is 18 March 2025